Capital International Investors’s Adaptimmune Therapeutics ADAP Stock Holding History

Capital International Investors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,321,200	Closed	-$5.63M	–	459
2021 Q2	$5.63M	Hold	1,321,200	–	–	﹤0.01%	435
2021 Q1	$7.02M	Hold	1,321,200	–	–	﹤0.01%	423
2020 Q4	$7.12M	Hold	1,321,200	–	–	﹤0.01%	416
2020 Q3	$10.5M	Hold	1,321,200	–	–	﹤0.01%	395
2020 Q2	$13.2M	Hold	1,321,200	–	–	﹤0.01%	369
2020 Q1	$3.59M	Buy	1,321,200 +694,200	+111%	+$2.3M	﹤0.01%	373
2019 Q4	$752K	Hold	627,000	–	–	﹤0.01%	381
2019 Q3	$947K	Hold	627,000	–	–	﹤0.01%	387
2019 Q2	$2.52M	Buy	627,000 +233,000	+59%	+$950K	﹤0.01%	381
2019 Q1	$1.69M	Hold	394,000	–	–	﹤0.01%	378
2018 Q4	$2.27M	Hold	394,000	–	–	﹤0.01%	370
2018 Q3	$5.34M	Buy	+394,000	New	+$4.13M	﹤0.01%	362

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital International Investors's ADAP Position: Q3 2021 in Review

Capital International Investors sold out of Adaptimmune Therapeutics (ADAP) in Q3 2021, closing a stake of 1,321,200 shares — an estimated $5.63M sold.

Capital International Investors first reported a position in ADAP in Q3 2018 and held it in 12 quarters. The position peaked at $13.2M in Q2 2020. 92 funds tracked by Wall St. Rank hold ADAP as of Q3 2021.

Capital International Investors reported no remaining Adaptimmune Therapeutics position as of Q3 2021 after selling out during the quarter.
Capital International Investors sold 1,321,200 Adaptimmune Therapeutics shares in Q3 2021, an estimated $5.63M.
Capital International Investors first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 12 quarters.
Capital International Investors's Adaptimmune Therapeutics position peaked at $13.2M in Q2 2020.
92 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2021.

Based on Capital International Investors's 13F filing for Q3 2021, filed 15 Nov 2021.